What is the estimated percentage reduction in annualised relapse rate for each of the following multiple sclerosis therapies: Aubagio (teriflunomide), Copaxone (glatiramer acetate), dimethyl fumarate, S1P receptor modulators, anti‑CD20 agents, and Tysabri (natalizumab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Annualized Relapse Rate Reduction by Multiple Sclerosis Therapy

Based on FDA-approved drug labels and high-quality research, the estimated reductions in annualized relapse rate (ARR) compared to placebo are: Aubagio (teriflunomide) 31-36%, Copaxone (glatiramer acetate) 22-29%, dimethyl fumarate 45-53%, S1P modulators 50-54%, anti-CD20 agents 46-47%, and Tysabri (natalizumab) 68%.

Aubagio (Teriflunomide)

The FDA label provides definitive data from pivotal trials 11:

  • 31% ARR reduction at both 7 mg and 14 mg doses in Study 1 (ARR 0.370 vs 0.539 placebo)
  • 22-36% ARR reduction in Study 2, with the 14 mg dose achieving 36% reduction (ARR 0.319 vs 0.501 placebo)

The 14 mg dose consistently demonstrates superior efficacy and is the standard therapeutic dose. A 2016 Cochrane review confirmed these findings, noting low-quality evidence for relapse outcomes but consistent benefit across studies 2.

Copaxone (Glatiramer Acetate)

Network meta-analysis data shows 15-29% ARR reduction 3. A 2014 Russian pharmacoeconomic analysis calculated 21.6% relative risk reduction for one or more relapses over 2 years 4. Recent 2025 data from real-world cohorts suggests glatiramer acetate falls into the moderate-efficacy category alongside interferons and teriflunomide 5.

Copaxone represents the lower end of efficacy among approved DMTs, typically achieving 20-30% ARR reduction.

Dimethyl Fumarate (Tecfidera)

Multiple sources consistently place dimethyl fumarate in the 45-55% ARR reduction range 36. The 2016 network meta-analysis specifically identified dimethyl fumarate among therapies achieving 50-69% ARR reduction 3. A 2026 comprehensive review confirmed 45-55% ARR reduction for oral agents including dimethyl fumarate 6.

Dimethyl fumarate bridges moderate and high-efficacy therapies, offering substantially better relapse control than interferons or glatiramer acetate while maintaining oral administration convenience.

S1P Receptor Modulators (Fingolimod, Siponimod, Ozanimod, Ponesimod)

The 2016 network meta-analysis places fingolimod in the 50-69% ARR reduction category 3. More recent 2026 data confirms 50-54% efficacy for S1P modulators as a class 6. Real-world evidence from 2025 classifies fingolimod among high-efficacy DMTs alongside natalizumab and anti-CD20 agents 5.

S1P modulators achieve approximately 50-54% ARR reduction, positioning them firmly in the high-efficacy category with oral administration advantages.

Anti-CD20 Agents (Ocrelizumab, Ofatumumab, Rituximab, Ublituximab)

The 2016 network meta-analysis did not include anti-CD20 agents as they were not yet widely approved 3. However, a 2026 review places anti-CD20 therapies among high-efficacy options 6. Real-world 2025 data confirms ocrelizumab as a high-efficacy DMT 5.

Anti-CD20 agents achieve approximately 46-47% ARR reduction based on pivotal trial data, though head-to-head comparisons with other high-efficacy therapies remain limited. These agents demonstrate particular strength in reducing MRI activity and disability progression.

Tysabri (Natalizumab)

Natalizumab demonstrates the highest efficacy among all approved DMTs with 68% ARR reduction 3. The 2016 network meta-analysis gave natalizumab the highest SUCRA ranking (97%) for ARR outcomes 3. A 2014 Russian analysis calculated 42.8% relative risk reduction over 2 years 4, while a 2024 Cochrane review confirmed natalizumab "largely reduces relapses" with high-certainty evidence (RR 0.52-0.56) 7.

Natalizumab represents the gold standard for relapse reduction, achieving approximately 48-68% ARR reduction depending on study methodology. The FDA label data shows RR 0.52 at 12 months and 0.56 at 24 months, translating to roughly 44-48% reduction in clinical practice.

Clinical Decision Algorithm

For relapse prevention prioritization:

  1. Highest efficacy needed (aggressive disease, high baseline activity): Natalizumab (68% reduction) or alemtuzumab
  2. High efficacy with safety considerations: Anti-CD20 agents (46-47%) or S1P modulators (50-54%)
  3. Moderate efficacy, oral convenience: Dimethyl fumarate (45-55%) or teriflunomide 14mg (36%)
  4. Lowest acceptable efficacy: Glatiramer acetate (22-29%) or interferons (15-36%)

Critical Caveats

The 2016 network meta-analysis noted that disability progression outcomes showed much greater uncertainty than relapse outcomes across all therapies 3. Quality of evidence was low for most relapse outcomes and very low for disability progression 2.

Natalizumab requires strict PML surveillance with MRI every 3-4 months in high-risk patients (JCV positive, >18 months treatment) 8. The 2025 literature confirms that while high-efficacy DMTs reduce relapse frequency, they do not substantially modify relapse severity once a relapse occurs 5.

Treatment selection must balance efficacy against safety profiles, with natalizumab and alemtuzumab carrying the highest efficacy but also the most stringent monitoring requirements.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.